alexa Eva Nagiec
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Eva Nagiec

 Drug Safety Research & Development, Pfizer WR&D., Cambridge, MA, USA

 Eva Nagiec is currently working at Drug Safety Research & Development, Pfizer WR&D, USA. His/her research interests reflect in JAKs and STATs in immunity, immunodeficiency, and cancer. He/She has wide range of publication and attended National or International Oral Presentations

Research Interest

 JAKs and STATs in immunity, immunodeficiency, and cancer


Attenuating Janus Kinases (JAK) by Tofacitinib Effectively Prevented Psoriasis Pathology in Various Mouse Skin Inflammation Models

Hak-Ling Ma, Katherine Masek-Hammerman, Susan Fish, Lee Napierata, Eva Nagiec, Saifur Rahman, Martin Hegen and James D Clark

Research Article: J Clin Cell Immunol 2013, 4: 176

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version